4D Molecular Therapeutics (FDMT) Gains from Investment Securities (2019 - 2026)
4D Molecular Therapeutics (FDMT) reported Gains from Investment Securities of $670000.0 for Q1 2026, down 75.92% year-over-year from $2.8 million in Q1 2025, and up 448.96% quarter-over-quarter from -$192000.0 in Q4 2025.
4D Molecular Therapeutics (FDMT) Gains from Investment Securities (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 8 years of Gains from Investment Securities data on file, last reported at $670000.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $670000.0, down 75.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.7 million (up 3.17% YoY), and the FY2025 annual result was $9.4 million, up 0.81% from the prior year.
- Gains from Investment Securities advanced to $670000.0 in Q1 2026 per FDMT's latest filing, from -$192000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $10.4 million in Q2 2025 and troughed at -$440000.0 in Q4 2022.
- A 5-year average of $2.2 million and a median of $285287.5 in 2022 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities jumped 940500.0% in 2024, then slumped 102.04% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at -$440000.0 in 2022, then soared by 100.23% to $1000.0 in 2023, then jumped by 940500.0% to $9.4 million in 2024, then tumbled by 102.04% to -$192000.0 in 2025, then jumped by 448.96% to $670000.0 in 2026.
- Business Quant data shows FDMT's Gains from Investment Securities at $670000.0 in Q1 2026, -$192000.0 in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 670,000.00 |
| Mar 31, 2026 | 670,000.00 |
| Dec 31, 2025 | -192,000.00 |
| Dec 31, 2025 | -192,000.00 |
| Sep 30, 2025 | 1.87 Mn |
| Sep 30, 2025 | 1.87 Mn |
| Jun 30, 2025 | 10.45 Mn |
| Jun 30, 2025 | 10.45 Mn |
| Mar 31, 2025 | 2.78 Mn |
| Mar 31, 2025 | 2.78 Mn |
| Dec 31, 2024 | 9.41 Mn |
| Dec 31, 2024 | 9.41 Mn |
| Sep 30, 2024 | 215,224.00 |
| Sep 30, 2024 | 215,224.00 |
| Jun 30, 2024 | 177,461.00 |
| Jun 30, 2024 | 177,461.00 |
| Mar 31, 2024 | 88,000.00 |
| Mar 31, 2024 | 88,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |